Millennium Management LLC Increases Stock Holdings in LivaNova PLC $LIVN

Millennium Management LLC lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 17.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,484,082 shares of the company’s stock after buying an additional 514,268 shares during the quarter. Millennium Management LLC owned 6.38% of LivaNova worth $214,376,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of LIVN. Hantz Financial Services Inc. raised its holdings in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares during the period. State of Wyoming purchased a new stake in shares of LivaNova during the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC raised its holdings in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. Quarry LP purchased a new stake in shares of LivaNova during the 3rd quarter valued at about $36,000. Finally, Covestor Ltd raised its holdings in shares of LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $78.50 on Thursday. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $80.96. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of 40.26 and a beta of 0.88. The business has a 50 day simple moving average of $70.01 and a 200-day simple moving average of $66.14.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same quarter in the previous year, the firm posted $0.88 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities research analysts expect that LivaNova PLC will post 3.73 earnings per share for the current year.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Stifel Nicolaus set a $80.00 target price on LivaNova in a report on Wednesday, February 25th. Robert W. Baird dropped their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Mizuho lifted their price objective on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Barclays lifted their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Needham & Company LLC lifted their price objective on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.